Last reviewed · How we verify
PTR-01
At a glance
| Generic name | PTR-01 |
|---|---|
| Also known as | Recombinant human collagen 7 (rC7), Recombinant collagen 7, rC7, Recombinant collagen 7 (rC7) |
| Sponsor | Phoenix Tissue Repair, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01) (PHASE2)
- A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa (PHASE2)
- A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTR-01 CI brief — competitive landscape report
- PTR-01 updates RSS · CI watch RSS
- Phoenix Tissue Repair, Inc. portfolio CI